After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The group is aiming for accelerated approval with the upcoming Alpacca trial.
Sunmo succeeds in a setting very similar to Starglo's.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
When your investment case breaks down, why not just do the decent thing?
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
